Cybin Inc

HELP

Market cap $226M

NEW YORK & TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 28, 2026, by Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP), please note references to Veterans Exploring Treatment Solutions (“VETS”) have been removed from the first, third and fourth paragraphs.  The corrected release follows:

Eric So, Interim CEO, to appear on panel entitled “The Next Wave of Health Innovation,” on May 4, 2026 NEW YORK and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Eric So, Helus Pharma's Interim Chief Executive Officer, will be speaking at the 29th Annual Milken Institute Global Conference on a panel entitled “The Next Wave of Health Innovation.” The Conference will take place May 3-6, 2026, at The Beverly Hilton & Waldorf Astoria in Los Angeles, and the panel will be held on Monday, May 4, 2026, at 2:30 p.m.

NEW YORK & TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced a collaboration with TARA Mind, which works with Veterans Exploring Treatment Solutions (“VETS”) to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program for Major Depressive Disorder (“MDD”), while expanding mental health awareness and access within the veteran community.

NEW YORK and TORONTO, April 23, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced the addition of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board.

I am upgrading Cybin Inc. to Buy, driven by recent regulatory and clinical tailwinds that favor its lead candidate, HLP003. HELP is positioned to benefit from expedited FDA pathways and increased institutional support, particularly for major depressive disorder and PTSD indications. The market undervalues HELP, trading near cash value with a 0.84x forward price-to-book and an $85M EV versus $195M in cash.

The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status, but reinforces a federal move toward medical, evidence-based framework for other alternative medicines, like cannabis, experts say.

Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating research into psychedelic-assisted therapies and expanding patient access for certain serious mental health conditions, including post-traumatic stress disorder (PTSD) and treatment-resistant depression. The executive order, signed by Trump on Saturday, directs the US Food and Drug Administration (FDA) Commissioner to prioritize review pathways for psychedelic drugs that have received Breakthrough Therapy designation for serious mental illnesses and meet criteria under a national voucher program designed to speed regulatory review.

NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today welcomed the White House Executive Order aimed at accelerating research, regulatory pathways, and patient access to psychedelic treatments.

This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Michael Cola is stepping down as Chief Executive Officer, effective immediately, at the request of the Board of Directors.

Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health ​regulators to speed up reviews of psychedelic drugs and boosted ‌federal research funding.